CTGF,PCNA,IL-1α及α-SMA在人胎儿皮肤无瘢痕愈合中的作用  

The Role of CTGF,PCNA,IL-1α and α-SMA in the Scarless Human Fetal Skin Repair

作　　者：宋雨健 李世荣[1] 刘剑毅[2] 

机构地区：[1]第三军医大学西南医院整形美容外科,重庆400038 [2]重庆医科大学附属第二医院整形美容科,重庆400042

出　　处：《中国皮肤性病学杂志》2016年第5期456-459,467,共5页The Chinese Journal of Dermatovenereology

摘　　要：目的动态观察结缔组织生长因子(CTGF),增殖细胞核抗原(PCNA),IL-1α以及α-平滑肌肌动蛋白(α-SMA)在人胎儿皮肤无瘢痕愈合过程中的表达及其与损伤时间的关系。方法将胎儿皮肤移植于裸鼠皮下,建立人胎儿皮肤无瘢痕愈合模型。并随机分为5组:未创伤组、创伤后1d组、创伤后2d组、创伤后3d组、创伤后7d组。通过免疫组织化学法检测创面中PCNA和α-SMA的表达变化,蛋白印迹法观察创面中CTGF的表达变化。通过酶联免疫吸附试验检测血浆IL-1α含量动态变化。结果创伤后,创面PCNA与α-SMA表达不断上调,创伤后7d开始下调。未创伤组、创伤后1d组、创伤后2d组、创伤后7d组CTGF蛋白表达差异无统计学意义(P>0.05),都呈现低表达;创伤后3d组CTGF蛋白表达上调,高于其他各组,差异有统计学意义(P<0.05)。创伤后1d到3d血浆IL-1α含量不断升高,创伤后7d急剧下降。结论 PCNA,α-SMA与IL-1α高表达与CTGF的低表达和人胎儿皮肤创伤后无瘢痕愈合相关。Objective To dynamically observe the expression of CTGF, PCNA, IL-1α and α-SMA in the scarless human fetal skin repair and to explore their relationship with injury times. Methods Human fetal skin was transplanted subcutaneously in nude mice,followed by establishment of a model of scarless human fetal skin repair. The mice were randomly divided into five groups, including no wound, 1,2,3,7 days after wound groups. The expression of PCNA and α-SMA were assessed by immunohistochemistry, and the expression of CTGF was determined by Western blotting. The levels of plasma IL-1α was measured by ELISA. Results After wound,the expression levels of PCNA and α-SMA were gradually increased, and began to decline 7 days after the wound. The expression levels of CTGF were lower with no significant differences among groups （P 〉 0. 05 ）except 3 days after wound at which the expression levels of CTGF was higher than the other groups（P 〈0. 05）. The levels of plasma IL-1α were gradually increased from day 1 to day 3 ,followed by a sharp decline on day 7 after wound. Conclusion Both high expression levels of PCNA,α-SMA and IL-1α, and the low expression levels of CTGF were associated with scarless human fetal skin repair.

关 键 词：胎儿皮肤 无瘢痕愈合 结缔组织生长因子 增殖细胞核抗原 α-平滑肌肌动蛋白 人白细胞介素-1α 

分 类 号：R619.6[医药卫生—外科学] R722.142[医药卫生—临床医学]